CYCC Cyclacel Pharmaceuticals
- 2.4900
- -0.3500-12.32%
Cyclacel Pharmaceuticals News
Cyclacel Pharmaceuticals Inc (CYCC) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
Earnings Call Summary | Cyclacel Pharmaceuticals(CYCC.US) Q1 2024 Earnings Conference
The following is a summary of the Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript:Financial Performance:Cyclacel reported cash and cash equivalents of $9.9 million as of the end
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (CYCC) Q1 2024 Earnings Call Transcript
10-Q: Quarterly report
Cyclacel Pharmaceuticals Q1 EPS $(2.27) Beats $(4.74) Estimate, Sales $29.00K
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate of $(4.74) by 52.11 percent. This is a 67.8 percent increase over losses
Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000
04:06 PM EDT, 05/14/2024 (MT Newswires) -- Earnings Flash (CYCC) CYCLACEL PHARMACEUTICALS Posts Q1 Revenue $29,000
Press Release: Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update - New Clinical Data to be Presented at ASCO Annual Meeting Highlighting Potential Precision Medicine Stra
Why JanOne Shares Are Trading Higher By 19%; Here Are 20 Stocks Moving Premarket
Shares of JanOne Inc. (NASDAQ:JAN) rose sharply in today's pre-market trading after the company announced plans to acquire ALT 5 Sigma Inc.The deal is projected to close in the week of May 13th.JanOne
Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results
Cyclacel Pharmaceuticals Files to Sell 15.2M Shares for Holders
Cyclacel Pharmaceuticals Is Maintained at Buy by Roth MKM
Cyclacel Pharmaceuticals Is Maintained at Buy by Roth MKM
Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11
Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target from $21 to $11.
Cyclacel Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 354.55% Roth MKM $21 → $11 Maintains Buy 12/19/2023 — Brookline Capital Downgrades Buy → Hold
Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules
BERKELEY HEIGHTS, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC, NASDAQ:CYCCP, ", Cyclacel", or the ", Company", )), a biopharmaceutical company developing innovative
Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Shares of Pinterest, Inc (NYSE:PINS) rose sharply in today's pre-market trading following strong first-quarter earnings and upbeat second-quarter guidance.Pinterest's first-quarter revenue increased n
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersAkanda (NASDAQ:AKAN) shares moved upwards by 69.1% to $0.16 during Wednesday's pre-market session. The company's market cap stands at $1.8 million. NanoVibronix (NASDAQ:NAOV) shares moved upwar
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersPredictive Oncology (NASDAQ:POAI) shares rose 36.4% to $1.95 during Tuesday's after-market session. The company's market cap stands at $7.9 million. Brainstorm Cell (NASDAQ:BCLI) shares moved u
Top Midday Gainers
Cyclacel Pharmaceuticals (CYCC) shares surged more than 47% after the company unveiled Tuesday a private placement of about 5 million shares and warrants, targeting gross proceeds of about $8 million.
Trending Stocks Today: Akili Surges 70.92%
April 30th - US stocks trending in regular trading hours.Gainers: $Akili(AKLI.US)$ surges 70.92% to $0.4 with a turnover of $33.74 million. $Global Mofy Metaverse(GMM.US)$ shoots up 53.71% to $1.43 wi
BKKT, CETX and SWVL Among Mid-day Movers
Analysis
Price Target
No Data
